1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) is sponsored by National Institute on Drug Abuse (NIDA). Through this NOFO, NIDA encourages research that addresses the institute's mission, including fostering the advancement and accelerating the growth of early-career scientists, and other individuals new to entrepreneurship, in the aging biotech landscape.
This grant supports small businesses in conducting research and development with strong potential for commercialization in areas relevant to NIH's mission.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs) interested in submitting SBIR Phase I and Fast-Track grant applications. All applications must propose clinical trial(s). Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, and $2,045,816 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNICHD forecast RFA-HD-28-005 (CAPSTONE), RFA-HD-28-006 (Learning Disabilities Research Centers), and RFA-HD-28-001 (Discovery Gateway) on October 20, 2026. All three are due around October 1, 2027. Here is what the incumbents hold and how challengers should prepare.
Read articleOn October 22, 2026, NIJ released three FY 2026 research solicitations: Drones as First Responders (O-NIJ-2026-172805, $3.5M, 5-6 awards, 36 months), Gangs and Organized Criminal Groups (O-NIJ-2026-172806, $3M, 5 awards, up to 60 months) and Elder Abuse, Neglect and Exploitation (O-NIJ-2026-172804, $1.8M, 2-3 awards, up to 60 months). Grants.gov is due November 30 and JustGrants December 7. The common thread is that each one rewards applicants who already have an operational law enforcement or practitioner partner. Here is how to read the three NOFOs and decide where to apply.
Read article